6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01856439 (ClinicalTrials.gov) | May 2011 | 14/5/2013 | Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease | A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease. | Parkinson's Disease | Drug: ProSavin | Axovant Sciences Ltd. | Oxford BioMedica | Terminated | N/A | N/A | All | 15 | Phase 1/Phase 2 | France;United Kingdom |
| 2 | EUCTR2007-001109-26-GB (EUCTR) | 04/11/2010 | 05/08/2010 | A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease | A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease | Patients with bilateral, idiopathic Parkinson's Disease | Product Name: ProSavin INN or Proposed INN: ProSavin | Oxford BioMedica (UK) Ltd | NULL | Not Recruiting | Female: yes Male: yes | 27 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 3 | EUCTR2009-017253-35-GB (EUCTR) | 20/08/2010 | 06/08/2010 | Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial. | A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease | Patients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ProSavin INN or Proposed INN: ProSavin | Oxford BioMedica (UK) Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 27 | United Kingdom | |||
| 4 | NCT00627588 (ClinicalTrials.gov) | January 2008 | 31/1/2008 | Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease | A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease. | Parkinson's Disease | Biological: ProSavin | Oxford BioMedica | NULL | Completed | 48 Years | 65 Years | Both | 15 | Phase 1/Phase 2 | France;United Kingdom |